California Oncology Weekly
A collaborative publication of the
Medical Oncology Association of Southern California, Inc.
and the
Association of Northern California Oncologists, Inc.
February 6, 2012 |
|
|
National News
- The Association of Community Cancer Centers (ACCC) submitted comments to CMS about the agency's Coverage with Evidence Development (CED) policies. ACCC expressed its belief that continued clinical research is essential to further improve patient care and must be a priority for all stakeholders involved in cancer care, including CMS. Accordingly, ACCC strongly urged CMS to ensure that CED does not restrict beneficiary access to appropriate care or impede innovation that will ultimately benefit Medicare beneficiaries. Read ACCC's comments at www.accc-cancer.org/advocacy/pdf/2012-CEDcomments.pdf. |
|
|
Policy Update - Do you want to improve your AUTONOMY when practicing medicine? MOASC and ANCO are working on your behalf to support the following bill to improve your ability to treat your patients in PAIN. AB 369 is a bill this year that would LIMIT INSURANCE COMPANIES ABILITY TO FORCE STEP THERAPY OR FAIL FIRST PROTOCOLS IN THE MANGEMENT OF PAIN. This bill would specifically do the following:
1) Prohibit a health care service plan or health insurer from requiring that a patient try and fail on more than two pain medications before allowing access to other pain medications prescribed by the physician, as specified;.
2) Authorize the duration of any step therapy or fail first protocol to be determined by the prescribing physician
We need your help for the successful passage of this bill into law. Please submit stories of your patients' insurance requiring them to try and fail on multiple pharmaceuticals in the management of pain. These stories may be used for media purposes to bring awareness to this issue and strengthen the chance of successful bill passage into law.
Medi-Cal
- A Federal judge has tentatively blocked Medi-Cal reimbursement cuts to doctors and other providers saying the cuts could cause irreparable harm. Courts have blocked various state budget cuts before. The state is appealing the judge's decision.
-The State Controller last week reported that the state of California will run out of cash by early March if immediate action is not taken to identify $3.3 billion in cash solutions. To meet this challenge, California will increase borrowing and institute short-term payment delays to universities, counties, and Medi-Cal providers. Therefore, the Department of Health Care Services (DHCS) will hold payments due to certain Medi-Cal fee-for-service providers on February 27, issuing them instead on March 5. DHCS will also hold payments on March 12, issuing them on March 19. For more information about the provider types impacted, please log on to the Medi-Cal website. DHCS understands that this difficult decision is painful for their valued provider partners, but Medi-Cal, as the state's second largest General Fund expenditure, must be part of the state's budget solution.
-Following are the correct payment hold dates, which reflect the information posted on the Medi-Cal website.
1) Payments scheduled for a warrant release date of March 1, 2012 (Electronic Funds Transfer [EFT] date of March 5, 2012) will be held until the warrant release date of March 15, 2012 (EFT date of March 19, 2012) and will be paid along with all services normally scheduled for payment that week.
2) Payments scheduled for a warrant release date of March 8, 2012 (EFT date of March 12, 2012) will be held until the warrant release date of March 22, 2012 (EFT date of March 26, 2012) and will be paid along with all services normally scheduled for payment that week.
3) Payments to Medi-Cal non-institutional providers will not be held.
For more information, please log on to the Medi-Cal website.
Medicare
-Practices are beginning to receive 2012 claims adjusted for unsuccessful 2011 reporting under the Medicare e-prescribing program. Physicians subject to the e-prescribing penalty will see an indicator "LE" on the remittance advice to denote the penalty. The remittance advice should also contain the following Claim Adjustment Reason Code (CARC) and Remittance Advice Remark Code (RARC):
CARC 237 - Legislated/Regulatory Penalty. At least one Remark Code must be provided (may be comprised of either the NCPDP Reject Reason Code, or Remittance Advice Remark Code that is not an ALERT).
RARC N545 - Payment reduced based on status as an unsuccessful e-prescriber per the Electronic Prescribing Incentive Program.
For more information on the 2012 penalty see the MLN Matters article.
to learn what practices need to know in 2012 to avoid penalties in 2013 and 2014.
-Based on Change Request (CR) 7670, the Claim Status and Claim Status Category Codes for use by Medicare Contractors were updated during the February 2012 meeting of the National Code Maintenance Committee. The code changes were also posted to the Web on or about March 1, 2011. Included in the code lists are specific details, including the date when a code was added, changed or deleted. Medicare Contractors will implement these changes on April 2, 2012.
|
|
The first MCN Physician Webinar, with Dr. Bruce Feinberg was held last Thursday, February 2. Dr. Feinberg who is an oncologist as well as Vice President and Chief Medical Officer of P4 Healthcare, introduced and discussed the development and organization of the clinical oncology pathway program within the MCN, as well as the various components of the MCN.
Following are the remaining webinar dates and times.To register, click on the link below and upon completed registration, you will receive a confirmation along with participation instructions.
Monday, February 6, 2012 at 5:30pm Pacific
http://registration.p4healthcare.com/MeetingRegistration/Physician/Meet-005616
Tuesday, February 7, 2012 at 12:00pm Pacific
http://registration.p4healthcare.com/MeetingRegistration/Physician/Meet-005617
Wednesday, February 8, 2012 at 5:30 pm Pacific http://registration.p4healthcare.com/MeetingRegistration/Physician/Meet-005618
Thursday, February 9, 2012 at 12:30pm Pacific
http://registration.p4healthcare.com/MeetingRegistration/Physician/Meet-005619
If you have any questions, please call the MOASC Office at 909-985-9061 ext. 1.
The industrialization of medicine is here, whether we like it or not. Government policy is directing physicians to be affiliated with hospitals, in ACO's or IPA type organizations. You are encouraged to become a Participating MCN Physician.
For our shared vision to be successful, it is vital that we create and maintain a robust network of MCN Physicians. We can take control of OUR OWN DESTINY and partner with fellow oncologists for continued access to the best oncology care in the world.
Thank you.
|
|
- The ANCO Board of Directors has elected the following officers (terms): President, Jeffrey Cronk, M.D. (Antioch, 2012-2013); Vice President, Daniel P. Mirda, M.D. (Napa, 2012-2013); Secretary, Bradley Ekstrand, M.D. (San Mateo, 2012); and, Treasurer, Robert L. Robles, M.D. (Pleasant Hill, 2012).
|
American Society of Clinical Oncology News
- ASCO would like to know how your practice is dealing with underwater drugs. Members are invited to e-mail practice@asco.org with the underwater drug's name and amount, their purchase price, and whether or not the coinsurance is being billed to the patient. Practices should also identify the reasons why the drug is underwater (supplier change, increase in purchase price).
- ASCO, in partnership with the Center for Health Workforce Studies of SUNY Albany, is conducting a Study of Oncology Practice Demographics and Trends. The study will analyze the scope of community practice by examining practice make-up, size, and affiliations, and will identify any trends in how these practices are being bought, sold, closed, merged with other practices or hospitals, or otherwise changing their practice model. In addition,a more limited analysis of how practices are adapting to administrative and reimbursement pressures will be conducted. |
American Society of Hematology News
- Under the terms of an ASH-supported provision contained in the health reform law, insurers would be prohibited from dropping coverage because an individual chooses to participate in a clinical trial and from denying coverage for routine care that they would otherwise provide just because an individual is enrolled in a clinical trial. The requirement would apply to all insurance products and to all clinical trials that treat cancer. ASH recently joined several organizations in submitting recommendations to CMS in advance of the agency's anticipated rule making to implement the clinical trials coverage provision. For more information, go to http://www.hematology.org/News/2012/7643.aspx.
|
California Medical Association News
- CMA's Practice Resources (February 2012) is now available at www.cmanet.org/resource-library/?filter&keyword=193. Highlights include Meet Your CMA Center for Economic Services Advocates, 2011 CES Advocacy Highlights, Blue Shield Launches Recontracting Initiative, The Coding Corner: When To Use and Not Use Modifier -59, Blue Cross Announces Changes to Prudent Buyer Contract, Are Your Visits Being Downcoded by Medicare?, Changes to United's Medicare Advantage Audit Program, Ask the Expert: Blue Cross Bilateral Billing.
- Contact: CMA's members help center, (800) 786-4262 or memberservice@cmanet.org to register for the following webinars:
2/15: HIPAA Risk Analysis for Meaningful Use: Be sure you are able to qualify for your electronic health record (EHR) incentive funding! Conducting a HIPAA Security Risk Analysis for most medical practices is a core Meaningful Use measure (relating to one of the 15 core objectives). This webinar provides detailed instruction on the steps needed to complete a risk analysis and practical solutions for even the smallest medical practice.
|
Industry News
- Genentech BioOncology is pleased to announce that the United States Food and Drug Administration has approved Erivedge for the treatment of adults with metastatic basal cell carcinoma or locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery and who are not candidates for radiation.
- Lilly Oncology is pleased to announce an update to the Alimta package insert to reflect data from a Phase 2 trial that suggests that the pharmacokinetics of Alimta in patients with third space fluid are consistent with those in patients without third space fluid.
- Millennium is pleased to announce that the United States Food and Drug Administration has approved an update to Velcade's package insert to include the subcutaneous method of administration (CPT code 96401) in all approved indications (multiple myeloma and mantle cell lymphoma after at least one prior therapy). Subcutaneous administration has a lower potential for grade 3-4 peripheral neuropathy. Additionally, the reconstitution process has changed to require less diluents.
Innovatix cordially invites healthcare professionals to participate in a jointly offered lunchtime CE teleconference; February 15, 2012 on Medicare and Medicaid Changes: An Update for Health Providers
Presented by:Brad Kile, PhD; S. Leigh Davitian, JD; Dumbarton Group and Associates
11:00am - 12:00pm Pacific. RSVP by Friday, February 10, 2012. Any questions please contact Shannon at (888) 258-3273 ext. 369 or ssteen@innovatix.com
-Cephalon is voluntarily recalling the below lot of TreandaŽ 25mg 8ml vials in response to the presence of particulate matter indentified as glass fragments found in a single Treanda 25mg vial. Lot # TB30111; CAT# 909-556; MAT# 5001929; NDC# 63459-0390-08
Please discontinue use of any affected vials and contact GENCO Pharmaceutical Services at 877.319.8965 for questions. If you are impacted by this recall, you will also receive a letter from McKesson Specialty Health.
-Allos Therapeutics, Inc. proudly sponsors the Allos Support for Assisting Patients
(ASAP) program, a reimbursement support and patient assistance program
designed to help patients and healthcare professionals gain appropriate access to
FOLOTYNŽ (pralatrexate injection). The ASAP program provides the following
services:
* Verification of Patient-Specific Insurance Benefits
* Pre-Submission Claims Review and Support
* Prior Authorization Assistance
* Coding and Billing Guidance
* Payer Research
* Denied and Underpaid Claims Assistance
* Patient Assistance Program for Qualified Patients
Monday-Friday, 9:00 am-8:00 pm, ET
1-877-ASAP102 (877-272-7102) - phone
1-877-801-0777 - fax
www.getASAPinfo.com
|
|
|
MOASC Calendar
MCN Webinar
(February 6, 2012
5:30pm)
MCN Webinar
(February 7, 2012
12:00pm)
MCN Webinar
(February 8, 2012
5:30pm)
MCN Webinar
(February 9, 2012
12:30pm)
Lunchtime Series Teleconference
2012 Human Resources Update
(February 29, 2012 12:00pm)
MOASC General Membership Meeting
(May 2, 2012
Los Angeles)
|
|
|
|
|
|
The Association of Northern California Oncologists (ANCO) is an association of hematologists/oncologists dedicated to promoting high professional standards of cancer care by providing a forum for the exchange of ideas, data, and knowledge. The Medical Oncology Association of Southern California (MOASC) is a leading oncology society that advances and protects the ability of cancer patients to obtain, and the ability of the oncology physicians to provide, optimal cancer care. The material contained in the California Oncology Weekly is intended as general information for ANCO and MOASC members. Because diagnostic, treatment, contracting, coding, and billing decisions should be made on a case-by-case basis, any such information contained in the California Oncology Weekly may not apply in any given situation. Members are encouraged to contact their own consultants or advisors to obtain specific advice on matters relating to contracting, coding, and billing. The information contained in California Oncology Weekly should not be used as a substitute for such advice.
MOASC: P.O. Box 161, Upland, CA 91785 | P (909) 985-9061 | F (909) 985-8581 | www.moasc.org
ANCO: P.O. Box 151109, San Rafael, CA 94915 | P (415) 472-3960 | F (415) 472-3961 | www.anco-online.org
|
|
|
|